Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

Bristol-Myers Squibb (BMY) is a highly respected pharmaceutical company. Technically speaking, the company was founded in 1989 through the merger of two older companies, both of which trace ...

In the first quarter, Bristol Myers' revenue grew by just 3% year over year to $11.5 billion. Eliquis and Opdivo accounted for more than half of that, racking up $6.3 billion in sales between them. It ...

Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...

Bristol Myers Squibb's financial results haven't been great in recent years. The giant drugmaker has been facing challenges, including several patent cliffs. New launches, pipeline progress, and a ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face ...